therefore , since both flecainide metabolites occur primarily in the conjugated form in plasma ( i.e. , free metabolite concentrations are low ) , it is unlikely that these compounds either potentiate flecainide 's antiarrhythmic action or increase susceptibility to drug toxicity in the clinical setting .
C0016229
flecainide 's
C0003195
antiarrhythmic